Peptimmune
Founded Year
2002Stage
Dead | DeadTotal Raised
$83.55MMissing: Peptimmune's Product Demo & Case Studies
Promote your product offering to tech buyers.
Reach 1000s of buyers who use CB Insights to identify vendors, demo products, and make purchasing decisions.
Missing: Peptimmune's Product & Differentiators
Don’t let your products get skipped. Buyers use our vendor rankings to shortlist companies and drive requests for proposals (RFPs).
Peptimmune Patents
Peptimmune has filed 1 patent.
Application Date | Grant Date | Title | Related Topics | Status |
|---|---|---|---|---|
11/17/2005 | 2/2/2010 | Autoimmune diseases, Immune system, Immunology, Clusters of differentiation, Transcription factors | Grant |
Application Date | 11/17/2005 |
|---|---|
Grant Date | 2/2/2010 |
Title | |
Related Topics | Autoimmune diseases, Immune system, Immunology, Clusters of differentiation, Transcription factors |
Status | Grant |
Latest Peptimmune News
Dec 5, 2016
Peptimmune, Inc. Mergers Acquisitions MA, Partnerships Alliances and Investment Report Prices from USD $350 14:35 EST 5 Dec 2016 | BioPortfolio Reports Home » Topics » Biotechnology Business » Latest News » Peptimmune, Inc. Mergers Acquisitions MA, Partnerships Alliances and Investment Report Prices from USD $350 Summary MarketLine's Company Mergers Acquisitions MA, Partnerships Alliances and Investments reports offer a comprehensive breakdown of the organic and inorganic growth activity undertaken by an organization to sustain its competitive advantage. MarketLines' Peptimmune, Inc. Mergers Acquisitions MA, Partnerships Alliances and Investments report includes business description, detailed reports on mergers and acquisitions MA, divestments, capital raisings, venture capital investments, ownership and partnership transactions undertaken by Peptimmune, Inc. since January 2007. Key Findings Provides intelligence on Peptimmune, Inc. MA, strategic partnerships and alliances, capital raising and private equity transactions. Detailed reports of various financial transactions undertaken by Peptimmune, Inc. and its subsidiaries since 2007. Information about key financial and legal advisors for Peptimmune, Inc.'s financial deals transactions. Financial deals tables and charts covering deal value and volumes trend, deal types and geographybased deal activity. ReasonsToBuy Access comprehensive financial deals data along with charts and graph covering MA, private equity, and partnerships and alliances. Form an independent opinion about Peptimmune, Inc.'s growth strategies through the organic and inorganic activities undertaken since 2007. Track your competitors' business structure and growth strategies. Related Biotechnology, Pharmaceutical and Healthcare News
Peptimmune Frequently Asked Questions (FAQ)
When was Peptimmune founded?
Peptimmune was founded in 2002.
Where is Peptimmune's headquarters?
Peptimmune's headquarters is located at 64 Sidney Street, Cambridge.
What is Peptimmune's latest funding round?
Peptimmune's latest funding round is Dead.
How much did Peptimmune raise?
Peptimmune raised a total of $83.55M.
Who are the investors of Peptimmune?
Investors of Peptimmune include Covera Ventures, MPM Capital, Boston Medical Investors, New Enterprise Associates, Silicon Valley Bank and 7 more.
Who are Peptimmune's competitors?
Competitors of Peptimmune include Tobira Therapeutics, Selecta Biosciences, MacroGenics, Micromet, Virdante Pharmaceuticals and 13 more.
Compare Peptimmune to Competitors
LaGray is engaged in the research and development of drugs for the treatment of endemic diseases in Sub-Saharan Africa.
Velbionanotech is designing drugs for various diseases such as Heart Disease, kidney stones, AIDS, Cancer, cosmetic generic products using a short fragment of DNA as a new type of drugs. These drugs are assembled in Nanochips and as nano particals for delivering in human body, which are affective in curing the sick/diseased and healing the injured. nVBN are working into New gene therapy procedures, DNA-based sensors, and other medical applications by using a new method developed to initiate and control chemical reactions on DNA strands. On the other hand silicon-based nanochips with itching and self-assembling techniques used to deliver drugs on the diseased molecules. The company are designing bionano products for the treatment of various diseases for Kidney stones,Gallbladder,Liver, Lungs,Heart etc mixing biology with traditional machinery. VBN Nanomedicine prepared for Heart disease, Galbladder, Liver, Kidney stones will have no side effect and it is safe to use since it is herbal. nn
Panacos is developing anti-infective products through discovery and development of small molecule oral drugs for the treatment of HIV and other major human viral diseases. Per the company, Panacos' proprietary discovery technologies are designed to combat resistance by focusing on novel targets in the virus life cycle, including virus maturation and virus fusion.
BioMs develops biologics for autoimmune diseases with a special emphasis on multiple sclerosis.
NexGenix Pharmaceuticals is developing drugs for cancer, neurodegenerative diseases, and neurofibromatosis.
AiRNA's focus is to develop RNAi drugs for cancer, inflammation, and infectious diseases.
Discover the right solution for your team
The CB Insights tech market intelligence platform analyzes millions of data points on vendors, products, partnerships, and patents to help your team find their next technology solution.